Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-12-07 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
Regulatory Filings Classification · 95% confidence The document is a press release issued by BioInvent International AB announcing the presentation of clinical trial data (BI-1808) at the ASH 2025 conference. It provides highlights of the study results, quotes from the CEO, and background information on the company and the drug candidate. It does not constitute a full financial report, a transcript of a call, or a regulatory filing of a specific form type. It is a standard corporate announcement of research findings, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-12-07 English
BioInvent presenterar lovande tidiga fas 2a-data på ASH 2025 för BI-1808 som monoterapi för behandling av CTCL
Earnings Release Classification · 100% confidence The document is a press release from BioInvent International AB announcing clinical trial results (Phase 2a data for BI-1808) presented at the ASH 2025 conference. While it contains detailed clinical data, it is structured as a corporate press release intended for public dissemination, including contact information, a disclaimer, and a link to the full PDF report. According to the 'Menu vs Meal' rule, since this is an announcement of findings rather than the formal scientific report itself, and it functions as a regulatory disclosure under the EU Market Abuse Regulation, it is classified as a Report Publication Announcement (RPA). Q4 2025
2025-12-07 Swedish
BioInvent presenterar uppdaterade fas 2a monoterapidata på ASH 2025 gällande BI-1808 för behandling av CTCL
Regulatory Filings Classification · 100% confidence The document is a press release from BioInvent International AB announcing that they will present updated Phase 2a clinical trial data for their drug candidate BI-1808 at the ASH 2025 conference. It provides a summary of the clinical findings and context regarding the drug's development. While it contains clinical data, it is a corporate announcement (press release) rather than a formal audit report, interim financial report, or investor presentation deck. Under the provided definitions, this fits best as a Regulatory Filing (RNS) as it is a standard corporate announcement regarding company activities and clinical progress, and it includes the mandatory disclosure language required by the EU Market Abuse Regulation.
2025-11-03 Swedish
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
Regulatory Filings Classification · 100% confidence The document is a press release issued by BioInvent International AB announcing that they will present clinical trial data at an upcoming medical conference (ASH 2025). It provides details about the trial, the drug candidate, and the presentation schedule. It does not constitute a full financial report, audit, or regulatory filing, but rather a corporate announcement regarding research progress. Under the provided classification system, general corporate announcements that do not fit into specific categories like earnings releases or M&A are classified as Regulatory Filings (RNS).
2025-11-03 English
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
Regulatory Filings Classification · 100% confidence The document is a press release from BioInvent International AB announcing that they will present updated clinical trial data at an upcoming medical conference (ASH 2025). It provides highlights of the study results but explicitly states that more comprehensive data will be disclosed in a poster presentation at a future date. As it is a corporate announcement regarding upcoming events and research updates, and does not constitute a full financial report or a transcript, it falls under the category of general regulatory announcements/press releases.
2025-11-03 English
BioInvent kommer att presentera tidiga fas 2a-data på ASH 2025 från den pågående studien med en trippelkombination av BI-1206, rituximab och Calquence i r/r NHL
Regulatory Filings Classification · 100% confidence The document is a press release from BioInvent announcing that they will present clinical trial data at an upcoming medical conference (ASH 2025). It provides highlights of the study results and details about the presentation, but it is not the full clinical report or a financial filing. According to the 'Menu vs Meal' rule, this is a corporate announcement regarding upcoming activities and data dissemination, which falls under the 'Regulatory Filings' (RNS) category as it is a standard press release issued in compliance with market abuse regulations.
2025-11-03 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.